The sodium-glucose cotransporter-2 (SGLT2) inhibitors are a newer glucose-lowering drug class used to treat type 2 diabetes that have been shown to improve cardiovascular outcomes [10]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.